Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination
Parés-Badell, Oleguer (Hospital Universitari Vall d'Hebron)
Zules-Oña, Ricardo (Hospital Universitari Vall d'Hebron)
Armadans-Gil, Lluis (Hospital Universitari Vall d'Hebron)
Pinós Tella, Laia (Hospital Universitari Vall d'Hebron)
Borras Bermejo, Blanca (Hospital Universitari Vall d'Hebron)
Otero, Susana (Hospital Universitari Vall d'Hebron)
Rodrigo-Pendás, José Ángel (Hospital Universitari Vall d'Hebron)
Vivet-Escalé, Martí (Hospital Universitari Vall d'Hebron)
Cossio, Yolima (Hospital Universitari Vall d'Hebron)
Agustí Escasany, M. Antònia (Hospital Universitari Vall d'Hebron)
Aguilera, Cristina (Hospital Universitari Vall d'Hebron)
Campins Martí, Magda (Hospital Universitari Vall d'Hebron)
Martínez Gómez, Xavier (Hospital Universitari Vall d'Hebron)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	The objective of this study was to assess the local and systemic adverse reactions after the administration of a COVID-19 mRNA-1273 booster between December 2021 and February 2022 by comparing the type of mRNA vaccine used as primary series (mRNA-1273 or BNT162b2) and homologous versus heterologous booster in health care workers (HCW). A cross-sectional study was performed in HCW at a tertiary hospital in Barcelona, Spain. A total of 17% of booster recipients responded to the questionnaire. The frequency of reactogenicity after the mRNA-1273 booster (88. 5%) was similar to the mRNA-1273 primary doses (85. 8%), and higher than the BNT162b2 primary doses (71. 1%). The reactogenicity was similar after receiving a heterologous booster compared to a homologous booster (88. 0% vs. 90. 2%, p = 0. 3), and no statistically significant differences were identified in any local or systemic reactions. A higher frequency of medical leave was identified in the homologous booster dose group vs. the heterologous booster dose group (AOR 1. 45; 95% CI: 1. 00-2. 07; p = 0. 045). Our findings could be helpful in improving vaccine confidence toward heterologous combinations in the general population and in health care workers.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Adverse reactions ; Booster dose ; COVID-19-vaccination ; Health care workers ; Mrna vaccines ; SARS-CoV-2
Publicat a:	Vaccines (Basel), Vol. 10 (july 2022) , ISSN 2076-393X

DOI: 10.3390/vaccines10081217
PMID: 36016105

10 p, 456.1 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats